Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lynparza Tablet (Olaparib) Regulatory Post-Marketing Surveillance

NCT04553926 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04553926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04553926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lynparza Tablet (Olaparib) Regulatory Post-Marketing Surveillance
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
February 1, 2021
Completion date
July 11, 2025
Enrollment
661 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, ovarian cancer, pancreatic cancer, prostate cancer